Mutational Damages in Malignant Lung Tumors
Yermekova S. Orazgaliyeva M. Goncharova T. Rakhimbekova F. Dushimova Z. Vasilieva T.
2023Asian Pacific Organization for Cancer Prevention
Asian Pacific Journal of Cancer Prevention
2023#24Issue 2709 - 716 pp.
Background: Today, genomic changes are an important cause of the occurrence, growth and progression of cancer. Technological advances in cancer genomic analysis platforms have made it possible to identify genomic alterations that may influence response to lung cancer treatment. Methods: The study examined tumor growth-inhibiting oncogenes and genes responsible for cell growth and division to identify mutations characteristic of malignant lung tumors. The mutations were studied in 400 postoperative samples after amplifying p53 and HRAS fragments and p53, p21Waf1, MDM2 mRNA. p53 or p21Waf1 were expressed in 50% of squamous cell carcinomas and adenocarcinomas of the lung. Results: The study examined tumor growth-inhibiting oncogenes and genes responsible for cell growth and division to identify mutations characteristic of malignant lung tumors. The mutations were studied in 400 postoperative samples after amplifying p53 and HRAS fragments and p53, p21Waf1, MDM2 mRNA. p53 or p21Waf1 were expressed in 50% of squamous cell carcinomas and adenocarcinomas of the lung. HRAS mutations were present in most squamous cell carcinomas and adenocarcinomas of the lung. EcoR1 and Pst1-restriction enzymes destroyed the RT-PCR product of the p53 and p21Waf1 mRNA and increased the level of detected mutations in lung adenocarcinoma to 75% and 50 %, respectively. EGFR mutations were more frequent in lung adenocarcinoma than in lung squamous cell carcinoma. Mutations in EGFR exons 19 and 21 found in 65 of 263 lung tumor samples indicated the tumor sensitivity to EGFR tyrosine kinase inhibitors. EGFR deletions in exon 19 occurred mainly in adenocarcinoma, L858R mutations in EGFR exon 21 were quite common in lung adenocarcinoma. Conclusion: The mutations detected in most squamous cell carcinomas and adenocarcinomas of the lung could be used to diagnose and predict the disease severity and targeted therapy efficacy.
adenocarcinoma , carcinoma , cell , Gene mutations , lung
Text of the article Перейти на текст статьи
Chair of Molecular Biology with Courses in Chemistry and Biochemistry, Kazakhstan-Russian Medical University, Almaty, Kazakhstan
Molecular Genetic Research Center, Kazakh Institute of Oncology and Radiology, Almaty, Kazakhstan
Department of Scientific Management and Grant Research, Kazakh Institute of Oncology and Radiology, Almaty, Kazakhstan
Department of Chemical and Biochemical Engineering, Institute of Chemical and Biological Sciences, Satbayev University, Almaty, Kazakhstan
Department of Research and Strategic Development, Kazakh Institute of Oncology and Radiology, Almaty, Kazakhstan
Chair of Molecular Biology with Courses in Chemistry and Biochemistry
Molecular Genetic Research Center
Department of Scientific Management and Grant Research
Department of Chemical and Biochemical Engineering
Department of Research and Strategic Development
10 лет помогаем публиковать статьи Международный издатель
Книга Публикация научной статьи Волощук 2026 Book Publication of a scientific article 2026